Next Article in Journal
The Properties of the Transient Outward, Inward Rectifier and Acetylcholine-Sensitive Potassium Currents in Atrial Myocytes from Dogs in Sinus Rhythm and Experimentally Induced Atrial Fibrillation Dog Models
Next Article in Special Issue
Current Utilization and Research Status of Herbal Medicine Sipjeondaebotang for Anemia: A Scoping Review
Previous Article in Journal
Correction: Kovács et al. ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of IKr. Pharmaceuticals 2023, 16, 488
Previous Article in Special Issue
Potential of Bitter Medicinal Plants: A Review of Flavor Physiology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 9
10.3390/ph17091136
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study

by
Aikaterini E. Mantadaki
1,*,†,
Stella Baliou
2,
Manolis Linardakis
1,
Elena Vakonaki
2,
Manolis N. Tzatzarakis
2,
Aristides Tsatsakis
2 and
Emmanouil K. Symvoulakis
1,†
1
Clinic of Social and Family Medicine, Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece
2
Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2024, 17(9), 1136; https://doi.org/10.3390/ph17091136
Submission received: 1 August 2024 / Revised: 22 August 2024 / Accepted: 27 August 2024 / Published: 29 August 2024
(This article belongs to the Special Issue Therapeutic Potential of Natural Products in Internal Diseases)
Browse Figures
Versions Notes

Abstract

:
Telomeres, the protective chromosomal ends, progressively shorten and potentially are implicated in the pathogenesis of age-related diseases. In type 2 diabetes (T2DM), telomere shortening may play an important role, but the whole ‘picture’ remains limited. From a therapeutic perspective, the phytonutrient quercetin appears to be clinically effective and safe for patients with T2DM. Considering the above, we aimed to examine whether quercetin could interfere with telomere length (TL) dynamics. One hundred patients with T2DM on non-insulin medications registered within a primary healthcare facility were stratified by age and sex and randomly assigned to either standard care or standard care plus quercetin (500 mg/day) for 12 weeks, succeeded by an 8-week washout period and another 12 weeks of supplementation. Of the 88 patients completing the trial, 82 consented to blood sampling for TL measurements. Health assessments and whole blood absolute TL measurements using quantitative polymerase chain reaction (qPCR) were conducted at baseline and study end, and the findings of this subcohort are presented. Quercetin supplementation was associated with a significant increase in mean TL (odds ratio ≥ 2.44; p < 0.05) with a strengthened association after full adjustment for potential confounders through multiple logistic regression analysis (odds ratio = 3.48; p = 0.026), suggesting it as a potentially promising supplementation option. Further studies are needed to confirm this finding, elucidating the underlying molecular mechanisms of quercetin.

Graphical Abstract

1. Introduction

Telomeres are nucleoprotein complexes capping the 23 pairs of linear chromosomes of each human cell. They contain tandem repeats of non-coding DNA motifs, specifically, in vertebrates, 5′-TTAGGG-3′ repeat units and their interacting protein partners, including a six-protein telomere-binding protective shelterin complex and a ribonucleoprotein (RNP), telomerase [1,2,3,4]. Importantly, the shelterin complex shields chromosomal ends of eukaryotic cells from recognition as double-stranded breaks (DSBs) [3]. The potential identification of telomeres as exposed DNA damage sites can lead to telomere fusion, degradation, recombination, or even telomere shortening (TS) [5], thereby compromising genomic stability [6].
More specifically, cellular proliferative rounds cause TS because of the end replication problem [7]. When telomeres reach a critically short length, they lose the protection of the shelterin protein complex, compromising their function. This leads to the triggering of the DNA damage response (DDR), inducing the activation of p53 transcription factor and the subsequent upregulation of cell-cycle inhibitors p16Ink4a and p21Cip1, resulting in cellular senescence, followed by apoptosis [8].
The most pronounced characteristic of senescent cells is their growth-arrested condition. In parallel, senescent cells are characterized by increased secretion of growth factors, cytokines, chemokines, proteases, and lipids, forming the senescence-associated secretory phenotype (SASP), thus sustaining low-grade inflammation [9]. On the other hand, uncapped telomeres can lead to numerous chromosome abnormalities and end-to-end fusion of chromosomes due to the absence of cell-cycle checkpoint mechanisms, resulting in genomic instability and widespread cell death [8].
Whereas TS is linked to aging and senescence, senescence does not always indicate cell aging [10]. Accordingly, a growing body of evidence proposes that the progression of age-related disorders may depend on the rate of TS [11,12,13,14,15,16]. Significantly, research has shown that telomere length (TL)—short, critically short, and critically long—is a recognized marker of biological aging and is considered a putative indicator of the cellular wellness of a person, with some predictive value for the risk of age-related illnesses like diabetes, osteoporosis, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, and some types of cancer [11,12,13,14,15,16,17]. For instance, TL has demonstrated utility in identifying patients with type 2 diabetes mellitus (T2DM) at risk of mortality [18]. The definitive role of TL in age-related diseases (ARDs) is still debated.
Relevant to this context, T2DM constitutes a global epidemic characterized by chronic dysglycemia, intertwined with heightened oxidative stress and inflammation [19], as elaborated elsewhere [20], a combination strongly correlated with accelerated TS. These interconnected processes may further contribute to genomic instability [21] and an increased vulnerability to vascular complications [22,23]. The interwoven relationship between telomere uncapping, senescence burden [23], and T2DM etiology underlines the necessity for innovative therapeutic interventions to preserve telomere integrity and mitigate disease progression in this population group.
Proceeding from this premise, emerging research suggests potential in targeting senescent cells and telomeres for the treatment and prevention of ARDs, and particularly T2DM [24]. Both senolytic and senomorphic therapies, designed to either eliminate senescent cells or mitigate their adverse effects, are being explored as possibly favorable interventions for age-associated morbidities [24,25].
The evolving field of telomere-targeted therapies, including senolytics, senomorphics, and potential telomerase activators, represents a promising research frontier in the pursuit of longevity and healthspan [26,27]. Nevertheless, telomerase activators have been implicated in oncogenesis concerns [27,28,29], hinting at a prerequisite for rigorous research and evaluation of the safety and regulatory efficacy of these interventions before their therapeutic potential in the context of healthy aging and age-related disease management can be fully understood.
The implications of telomere dysfunction and cellular senescence possibly associated with ARDs have instigated investigations into potential senotherapeutic interventions [8,30]. Quercetin, a flavonoid found ubiquitously in plant-derived dietary sources [31], has attracted considerable research interest as a potential therapeutic agent for mitigating cellular senescence [32,33,34]. This polyphenolic compound with potent antioxidant and anti-inflammatory properties [35,36,37] may exert a dual, pleiotropic action as both a senolytic and senomorphic [32,33,34]. The former indicates it can function by selectively inducing apoptosis of senescent cells and the latter implies the potential ability of modulating, particularly attenuating the SASP, possibly rendering it a promising candidate for mitigating the adverse consequences of cellular senescence and telomere dysfunction and potentially paving the way for innovative phytotherapeutic interventions in the supportive care management of ARDs.
The complex interplay between telomere dysfunction and T2DM pathophysiology generates mixed methodology hypotheses, justifying a combined laboratory and clinical approach to synchronically examine the variation of telomere status and disease progression in this vulnerable population group. Therefore, leveraging our prior work elucidating the safety and clinical efficacy aspects of quercetin nutritherapy [20,38], revealing a presumed improvement in standard risk factors, this randomized controlled before-and-after trial further delves into the potential of quercetin to modulate whole blood absolute TL in patients with T2DM, providing exploratory insights and putatively representing a novel nutritional senotherapeutic piece of knowledge to ARDs.

2. Results

Of the 88 patients concluding the trial [20], 82 voluntarily consented to blood sampling for absolute whole blood TL measurements by quantitative polymerase chain reaction (qPCR), as shown in the report-specific flowchart (Figure 1). This subsequent analysis was therefore confined to this subcohort of 42 control and 40 intervention participants. Aligning with the study design, adherence to the nutraceutical allocation was consistent within the treatment group.
The baseline characteristics of the 82 randomized patients with T2DM consenting to blood sampling for whole-blood TL measurements are displayed in Table 1 using chi-squared and Student’s t-tests for comparison. The mean age of participants was 66.3 ± 7.4 for the intervention and 67.8 ± 6.2 years for the usual care group. The groups were well-balanced in sex, age, and nationality attributes (p > 0.05). Both groups were under treatment with oral antidiabetic pills (viz. metformin, SGLT-2 and DPP-4 inhibitors, sulfonylurea, or their combinations, p > 0.05), while eight in each group were additionally treated with GLP-1 agonists (p = 0.913). A balanced distribution of lifestyle risk factors between both groups was noted, without statistically significant intergroup differences in their prevalence (smoking, alcohol consumption, high body weight, physical inactivity, and lack of fruit consumption; p > 0.05). Also, no significant differences were discerned between the groups regarding the prevalence of multimorbidity, polypharmacy, or the mean duration since T2DM diagnosis (p > 0.05). Specifically, the occurrence of the most common age-related conditions (hypertension, dyslipidemia, chronic inflammatory airway diseases; CIADs, depression and anxiety disorder) was similar (p > 0.05) between the study groups of this subcohort.
Overall, both groups were comparable at baseline, as demonstrated in Table 1 and Table 2. The inter- and intra- group comparisons of health indicators of the 82 patients with T2DM randomized to intervention and control groups included in this analysis, from the starting point to the endpoint (8 months) of the study are presented in Table 2. The intervention group demonstrated a statistically significant improvement in night-time sleep duration, while the control group experienced a decrease (0.8 vs. −0.5 h, p < 0.001). Health self-assessment scores significantly improved in the intervention. In contrast, the control group experienced a decrease, yielding a statistically significant intergroup difference (1.5 vs. −0.6, p < 0.001). Between the two groups, no significant changes were observed in body mass index (BMI) values (p > 0.05). Systolic blood pressure significantly decreased in the intervention group, while it increased in the control group (−6.3 vs. 0.5 mmHg, p = 0.02). Neither inter- nor intra-group comparisons revealed significant alterations in diastolic blood pressure (p > 0.05). Between-group analyses showed no significant changes in total cholesterol, whereas the cholesterol ratio insignificantly decreased in the intervention group (p = 0.07). A statistically significant decrease in the glycated hemoglobin (HbA1c) measures of the intervention group was observed compared to the control group (−0.28 vs. 0.03%, p = 0.008). Average TL per chromosome end significantly increased in the intervention group (from 5.11 ± 1.35 to 5.63 ± 2.08 kb), while the control group experienced a decrease (5.19 ± 1.76 to 4.88 ± 1.19 kb; 0.52 vs. −0.31 kb, p = 0.048) over the eight-month supplementation period.
The percentage frequencies of TL changes, as increase or decrease, from baseline to the endpoint at 8 months for the 82 consenting patients analyzed in this report are illustrated in Figure 2. A significant change in TL dynamics was observed between the two groups as the intervention group exhibited a higher frequency of TL increase compared to counterparts (57.5% vs. 35.7%) (p = 0.048).
The results of multiple logistic regression analyses examining the prognostic factors associated with an increase in average TL (versus decrease) over the 8-month subcohort-study period are delineated in Table 3. Except for the crude model, three more models were constructed, each incorporating a progressively comprehensive set of covariates. In the unadjusted model (crude), the intervention group exhibited a 2.44-fold higher odds of TL increase compared to the control group (p = 0.05). After adjusting for baseline TL through model 1, the intervention group maintained a 2.87-fold increased odds of TL increase (p = 0.036). Even after further accounting for sex and age attributes as additional confounders, the association was consistently statistically significant (model 2, odds ratio; OR = 2.90, p = 0.04). When the model included an expanded range of confounders, i.e., lifestyle risk factors, multimorbidity, polypharmacy, and years since T2DM diagnosis, an amplified effect was demonstrated (OR = 3.48, p = 0.026) (model 3). Furthermore, higher baseline TL was consistently related with a significantly decreased likelihood of telomere increase in patients with T2DM after controlling for multiple covariates (OR < 1.00, p < 0.01).

3. Discussion

The results deriving from this subcohort are in parallel with our prior clinical findings [20,38], further solidifying the promising potential of quercetin as an adjunct nutritional senotherapeutic intervention for T2DM. They also add a compelling layer of evidence, expanding previous knowledge on the overall health status, underscoring its role in disease progression and compelling further investigation of the translational senolytic potential of quercetin on diabetic sequalae. As a matter of fact, to the best of our knowledge, our study constitutes the first randomized controlled before-and-after trial to assess the impact of quercetin on absolute TL of an age-related disease while concurrently examining clinical features in primary care attendees.
Only one randomized controlled trial (RCT) on seniors with metabolic syndrome has evaluated the influence of quercetin supplementation on leukocyte TL (LTL) but found no changes post-supplementation [39]. Nevertheless, the limited 3-month study period, as well as the lower daily dosage of 240 mg, might have constrained the imprint of this intervention. Conversely, in our study, the intervention group received quercetin intermittently: for 12 weeks, followed by an 8-week washout period and another 12 weeks of supplementation. Another point for discussion within the limitations of the mentioned study includes its measurement of TL, which was based on a relative TL evaluation (T/S ratio) [40,41,42,43,44].
This analysis provides initial findings suggesting that quercetin could offer advantageous nutriprotective benefits in a population with T2DM. Specifically, within this subcohort of 82 patients who underwent TL blood sampling, significant positive effects were noted on TL and clinically relevant improvements, including nocturnal sleep duration and subjective health status. There was also a decrease in systolic blood pressure and glycated hemoglobin and a marginally insignificant decrease in the cholesterol ratio. BMI, diastolic blood pressure, and total cholesterol remained largely unchanged.
As the potential molecular mechanisms underlying these protective effects have been extensively explained in our prior publications [20,38] and the pre-defined primary endpoint of this study was the impact on TL [45], the current analysis will not reiterate previously explored mechanistic aspects. It will instead focus on a proof-of-concept approach.
Our results regarding the absolute TL of whole blood samples are consistent with previous research in the general population of similar age range [43,46,47,48,49]. Notably, our results lean towards the lower end of the observed TL distribution of healthy populations [50,51], aligning with the previous literature on the association between shorter telomeres and diabetes [52,53,54,55]. The observed increase in the absolute TL measurements within the intervention group, independent of potential confounders, suggests a potential reduction in the proportion of the senescence-inducing telomeres, potentially conferring beneficial effects on cellular health and longevity. While our methodology provides a measure of telomere length, it is also possible that the removal of cells with shorter telomeres could contribute to the observed net increase. Therefore, the detected increase in TL can only be discussed as a preliminary observation.
It is also important to highlight that when measuring TL in whole-blood samples, the absolute TL measurement primarily reflects the TL of the most abundant cells in blood, which are circulating immune cells, while other cell types present in blood typically do not contribute significantly to the overall measurement. The senolytic effects of quercetin have been investigated in endothelial and adipose tissue cells [56,57] to date, yet the evidence is less well-established regarding the circulating immune cells. Our exploratory results underline the necessity for further biological studies in this nascent field.
The existing literature on the consequences of different nutritive interventions on TL reveals divergent findings, with scant evidence from RCTs [58] demonstrating both beneficial and nuanced effects. Notably, the D-Health Trial, involving regular monthly vitamin D supplementation, did not provide a protective effect on telomere attrition in older individuals already possessing sufficient levels of vitamin D [59]. Similarly, in a subcohort of the double-blind, n-3 PUFA RCT of 106 subjects over 4 months, no significant differences in TL were observed between the intervention and control groups [60]. Conversely, a 6-month RCT including 33 adults over 65 years old with minor neurocognitive deficit suggested that omega-3 fatty acid intake may attenuate TS [61]. A two-year-long RCT with 162 participants examining LTL after walnut consumption indicated a potential trend towards LTL preservation in older adults, possibly associated with its alpha-linolenic acid and polyphenol-rich content [62]. Furthermore, a smaller, one year-long study with 65 individuals provided preliminary evidence of correlation between the supplementation with vitamins of the B-complex and the mitigation of telomere attrition [63].
Our findings add to the limited body of research on senescence-targeting interventions exploring telomere biology in humans [64]. Focusing on the available senolytic interventions, a prospective study investigated the use of hyperbaric oxygen therapy (HBOT) in 35 healthy adults over 64 years old. This study employed flow-fluorescence in situ hybridization (Flow-FISH) analysis of peripheral blood mononuclear cells (PBMCs) and reported a significant increase in TL across immune cell subsets, specifically, T helper cells, cytotoxic T cells, natural killer cells, and B cells, with the latter exhibiting a more pronounced effect [65]. In contrast, a longitudinal study evaluated the combination of dasatinib and quercetin (D + Q) for six months, followed by an identical six-month regimen plus fisetin one year later, in 19 participants utilizing a DNA methylation (DNAm)-based clock. Distinct effects on TL were revealed. The initial regimen resulted in a decrease in TL at the 3- and 6-month time points, whereas the subsequent addition of fisetin appeared to mitigate TS after one year of treatment [64].
An intriguing perspective unveiled from this analysis urges to be elucidated: the interconnection between favorable clinical and cellular homeostasis aspects following quercetin supplementation. These comprised ameliorated nocturnal sleep duration, well-being perception, blood pressure normalization and improved glycemic regulation. Interestingly, TS has been associated with poor sleep patterns [66,67,68], compromised psychophysiological health [69,70,71], hypertension [72,73], and impaired glycemic control [54,74].
The observed positive effects of quercetin on TL could be attributed to various, interrelated mechanistic reasons with yet unresolved intricacies and primarily to its capacity for mitigating oxidative stress and inflammation [35,36,37], both of which are known to accelerate TS [75,76]. This antioxidant protection potentially enables enhanced telomerase stability [3,77]. Furthermore, building upon the previously discussed contextualized rationale regarding its potential senolytic and senomorphic properties [32,33,34], quercetin may exert a preventive effect on TS by reducing the burden of senescent cells. Additionally, research suggests that quercetin could act as a regulator of key signaling pathways crucial for preserving cellular homeostasis, modulating sirtuins (especially activating SIRT1 and potentially dose-proportionally regulating SIRT6 [78,79,80,81]) and the AMP-activated protein kinase (AMPK) enzyme [82,83,84].
Remarkably, quercetin might exert intricate effects on telomerase activity, suggesting a potential for differential modulation in diverse cellular milieux and dose-dependent contexts, as bolstered by its polyphenolic property [85]. Although the relevant research is rapidly evolving, highlighting the necessity for further biological studies, the current literature proposes that in cancer cells, it inhibits telomerase activity [86,87,88], consistent with findings for other flavonoids [85,88], while concurrently selectively modulating the expression of POT1, TRF1, and TRF2 proteins [89]. This inhibitory effect in cancer cells, combined with an observed activation of hTERT in certain cell lines [90], raises the intriguing possibility that it may preferentially regulate telomerase activity in healthy human cells [91], potentially favoring the activation of hTERT or the expression of telomere-protective proteins and subsequent telomere elongation. Whether this proposed selective telomerase activation hypothesis is valid and translates to tangible benefits in telomeric elongation could initiate a pathway for ongoing investigation. Additionally, the literature supports its influence on epigenetic modifications, viz. DNA methylation, histone acetylation, and microRNA regulation [91,92], hinting at a broader role in regulating cellular processes involved in telomere maintenance.

Study Strengths and Limitations

A key strength of our study lies in its comprehensive assessment of telomere dynamics in T2DM, employing accurate, high-throughput absolute TL measurements by qPCR [40,41,42,43,44]. Considering our RCT prioritized the metabolic and clinical implications in a substantial population with T2DM, we opted for the more practical qPCR measurements through commercial kits, which are informative at the cell-population level. Even though qPCR provides an individual’s average telomere data based on the specific amplification of telomere repeats, it is not considered a precise method [40]. The primary limitation of qPCR is its incapacity to offer details regarding the TL variations among cells and chromosomes [40]. For this reason, quantitative fluorescence in situ hybridization (qFISH) is the preferred technique for high-resolution evaluation of TL of cells in each chromosome at the single-cell level [93,94]. In addition, qFISH effectively captures even the extremely short telomeres [95], unveiling more precise TL alterations at the single-cell level [96,97] and could provide a more nuanced explanation of the observed effect on TL. While our study involved an open-label, non-placebo-controlled design, the primary outcome, TL, was directly measured using objective qPCR assays. Likewise, the staff conducting hematology tests for secondary outcomes were blinded to group allocations, further minimizing the risk of measurement bias. Furthermore, this study was prospectively registered within the International Standard Randomized Controlled Trial Number (ISRCTN) registry [45]. This work is the content of an ongoing PhD thesis, with no external funding, with permissions from all involved institutional bodies, after full protocol submission, and later performed in alignment with its protocol design requirements. Homogenous procedures across all study groups enabled for a standardized evaluation of the ascertained outcomes. Additionally, an intention-to-treat (ITT) approach was employed, which attenuates the potential for overestimation of intervention efficacy [98].
By incorporating absolute TL measurements from whole blood alongside relevant clinical biomarkers, we have attempted a deeper, integrative understanding of the intricate relationship between aging processes and T2DM. This approach provides unique, multilateral insights into how senotherapy may palpably influence telomere dynamics and interact with other cardiometabolic health parameters, potentially targeting disease progression and improving outcomes in patients with T2DM. Also, the 8-month rigorous RCT design, despite the availability of a subcohort of samples, equipped us with a power of detection of at least 80%, which should be mentioned. Moreover, the models fitted in the multiple logistic regression analysis were adjusted for several confounders. Another limitation is that we could not assess further biological variables which might have been proven helpful to explain the underlying mechanisms. Given the emerging role of cellular senescence in both the development of diabetes [99] and its complications [23], our study offers potentially relevant insights into promising therapeutic avenues for this disease. Nonetheless, our study design was not specifically tailored to address these elements. Future studies should include more extensive, larger-scale, blinded, placebo-controlled, dose–response assessment designs examining disease progression and complications so as to verify the senolytic results and to enable further decipherments.

4. Materials and Methods

4.1. Study Design, Participants, Phytonutrient

We conducted a prospective, randomized controlled before-and-after trial within a primary healthcare (PHC) facility in Heraklion, Crete, in the context of a PhD thesis of the Clinic of Social and Family Medicine, Department of Social Medicine, School of Medicine, University of Crete, with the aim to evaluate the clinical utility and potential of quercetin supplementation as an adjunct support for patients managing T2DM. Data were collected from registered patients within the 4th Local Health Unit of Heraklion (TOMY). Participants over 50 years old with an established diagnosis of T2DM and treated with non-insulin medications were enrolled in the trial between February and May 2023 after providing informed consent, as described in our previous report [20].
Of the 324 patients initially identified as candidates, 100 were ultimately randomized into two parallel groups after stratified randomization (1:1) ensuring balanced age and sex distribution: a control group (CTR, n = 50) receiving standard care and an intervention group (INT, n = 50) receiving quercetin dihydrate (500 mg/day) supplementation for two 12-week periods interspersed with an 8-week washout. Specifically, the INT received quercetin as an adjunctive treatment to their existing regimen and the control group did not, while both groups received uniform guidance. Further details on the phytonutrient supplement specifications and strategies to enhance participants’ adherence to protocol requirements were formerly reported [20,38]. Participant flow throughout the randomized trial has also been delineated elsewhere [20], outlining reasons for attrition. Scheduled follow-up assessments were conducted in person: at baseline, at 3 months for a randomized subset, and at study endpoint. Participants underwent comprehensive health evaluations, and standardized fasting blood samples were collected at baseline and study conclusion, as mentioned in our previous work [20,38]. Participants self-rated their overall health status on a scale of 0 to 10, with 0 indicating extremely poor and 10 reflecting optimal health, for the needs of the health-self-assessment variable. TL was identified as the primary outcome of this study, as detailed in the study registry [45]. Of the 88 participants reaching the final study endpoint at 8 months, 82 consented to venipuncture for collection of blood samples in ethylenediaminetetraacetic acid (EDTA)-coated tubes.
Following gentle inversion to ensure thorough mixing, samples were securely stored at −20 °C, under strict quality and tracing control mandates, until genomic DNA extraction. Genomic DNA was subsequently isolated from the whole blood of these consenting patients. qPCR quantified absolute TL, and the resulting data are outlined in the current report.

Sample Size Estimation

Sample size estimates were determined at the clinical design stage as 45 participants per group using G*Power 3.1.9.7 [100,101], treating TL as a continuous variable, in consistency with calculations in methodologically comparable studies [60,102,103,104,105,106], and exceeding that of similar studies [107,108,109]. A post-hoc power analysis was conducted on the available sample, yielding a statistical power of at least 80%.

4.2. Telomere Length Evaluation

TL assessments were conducted at the Department of Morphology, Laboratory of Toxicology, School of Medicine, University of Crete, which has established expertise in this research field [110,111] under consistent experimental conditions.

4.2.1. DNA Extraction

Genomic DNA was extracted from human whole-blood samples using the NucleoSpin® Blood QuickPure kit (Macherey-Nagel, Düren, DE (Germany), catalog #740569.250, LOT no: 2311-003, exp.: 2026-02), as per manufacturer’s recommendations. All samples were lysed with proteinase K and lysis buffer at 70 °C and to ensure optimal DNA yield, an extended lysis protocol was implemented, involving further incubation for 30 min with intermittent vortexing. Following lysis, DNA was bound to silica columns, washed, and eluted with pre-warmed elution buffer, according to the kit’s instructions. DNA purity and integrity were evaluated utilizing a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and accompanying NanoDrop ND-1000 v.3.3 software (Coleman Technologies Inc., Langley, BC, Canada). Successfully extracted samples were then diluted to a working concentration of 5 ng/μL for downstream analysis and subsequently short-term stored at 4 °C.

4.2.2. Absolute Quantification of Telomere Length

qPCR quantified the absolute TL. Specifically, the Absolute Human Telomere Length Quantification qPCR Assay Kit (ScienCell, Carlsbad, CA, USA, Cat #8918) was used to quantify the average length of telomeric ends on each chromosome of pure genomic DNA (gDNA), isolated from human blood samples, as described previously. qPCR was performed on a Stratagene Mx3005P qPCR thermocycler (Agilent Technologies Inc., Santa Clara, CA, USA) through MxPro v.4.1.0.0 software. Following the manufacturer’s protocol, two qPCR reactions were performed for each gDNA sample: one with telomere-specific (TEL) and one with single-copy reference (SCR) primers, targeting a 100 base-pair region on chromosome 17 for internal normalization. A reference gDNA sample of known TL (REF) provided in the kit served as a standard. Duplicate qPCR reactions were performed for each gDNA sample (4 qPCR reactions in total) on the same 96-well-plate, consistent with prior methodology [104,112], using water as the negative control and reference gDNA (REF) as the positive control in each run. In more detail, reactions contained 5 nanograms of gDNA template, combined with 2X GoldNStart TaqGreen qPCR Master Mix and either TEL or SCR primers. Samples from the intervention and control groups were run simultaneously on the same well plate. Additionally, minimal variation in Cq values was tolerated for all samples, while the entire experimental analysis was repeated in independent assays to ensure reliability and performance reproducibility [105,113,114,115]. The qPCR thermal cycling parameters consisted of a ten-minute preliminary denaturation at 95 °C, followed by 32 cycles of denaturation at 95 °C (20 s), a 20 s annealing at 52 °C, and a 45 s extension at 72 °C. Relative differences in TLs were calculated using the Livak comparative (ΔΔCq) method [116,117] through tabulation. Briefly, the difference in average quantification cycle (Cq) values between the target and reference samples was calculated for both telomere (TEL) and single-copy reference (SCR) amplicons (ΔCq TEL and ΔCq SCR). The ΔΔCq value was then obtained by subtracting ΔCq SCR from ΔCq TEL. The fold change in TL relative to the reference was calculated as 2−ΔΔCq. Absolute TL per diploid genome was determined by multiplying the relative TL by the known TL of the reference gDNA sample. Average TL (in kb) per chromosome end was calculated by dividing the total TL per diploid genome by 92. Amplification plots derived from standard curves assessed the efficiency and specificity of the qPCR reactions.

4.3. Statistical Analysis

Statistical analyses were conducted using the SPSS software (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA: IBM Corp). Data normality was assessed with Blom’s method (Q-Q plot), and χ2 and Student’s t-test methods were implemented, respectively comparing categorical and continuous data between the two groups. Most of the results were presented with measures of location and dispersion or frequency distributions. Four multiple logistic regression models were constructed to assess the association between quercetin intake and the likelihood of TL increase, considering potential confounding factors, including established lifestyle-habit risk factors, previously associated with health outcomes [118,119,120]. The improvement in explained variance for TL changes was demonstrated by increasing Nagelkerke R2 determination values across sequential models, indicating a progressively enhanced model fit [121].

4.4. Ethical Compliance and Approvals

This RCT was registered with ISRCTN [45] and received ethical approval from the University of Crete Research Ethics Committee (REC-UoC; 104/20-08-2021) and the 7th Health District of Crete, Heraklion (6380-14/02/2022), while aligning with international ethical and regulatory standards [122,123,124,125,126,127]. This RCT also adhered to the International Council for Harmonization (ICH) E18 guideline [128] on genomic sampling and data management, adopted by the European Medicines Agency [129].

5. Conclusions

Our study provides valuable insights through unifying hypotheses and integrating clinical parameters and telomere senescence pathways. We offer a deeper understanding of the relationship between aging processes and T2DM to assess the impact of quercetin intake in patients with T2DM. In this context, we highlight the potential of incorporating quercetin into PHC supportive interventions for T2DM. We report that quercetin, as a complementary phytonutritive senotherapy alongside standard pharmacological regimens, might propose an integrative care plan, as evidenced by its emerging potential to significantly increase the average telomere length of the intervention group, along with improvement of sleep, well-being perception, blood pressure and glycemic regulation. These findings create possibilities for targeting disease progression and improving patient outcomes, although future larger-scale, multi-center, placebo-controlled, dose–response assessment and blinded studies are needed for validation. Importantly, our work indirectly showcases how lifestyle choices might affect the progression of T2DM and underscores the value of implementing TL measurements into clinical assessments for T2DM populations. This opens avenues enabling specific, informed research initiatives, and early identification of aberrant telomere shortening before and after overt clinical manifestations, potentially paving the way for ‘personalized medicine’ and multi-omics approaches to learn more about disease trajectory and monitoring.

Author Contributions

Conceptualization, A.E.M. and E.K.S.; methodology, A.E.M. and E.K.S.; software, M.L.; validation, A.E.M., M.L., S.B., and E.V.; formal analysis, A.E.M. and M.L.; investigation, A.E.M., S.B., M.N.T., E.V., and A.T.; resources, A.E.M., S.B., M.N.T., and A.T.; data curation, A.E.M., M.L., and S.B.; writing—original draft preparation, A.E.M. and E.K.S.; writing—review and editing, A.E.M., M.L., S.B., E.V., M.N.T., A.T., and E.K.S.; visualization, A.E.M., M.L., S.B., and E.V.; supervision, E.K.S.; project administration, A.E.M. and E.K.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This randomized controlled trial, registered and curated in the International Standard Randomized Controlled Trial Number (ISRCTN) registry, aligned with the Declaration of Helsinki principles and received permission to conduct from the Research Ethics Committee of the University of Crete (REC-UoC) (protocol code 104; approval date 20 August 2021) and the 7th Health District of Crete, Heraklion (6380-14/02/2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study. Written informed consent was obtained from the patients to publish this paper.

Data Availability Statement

The principal investigators retained exclusive access to the trial dataset, which was maintained under stringent security protocols on protected servers housed at the University of Crete. External researchers may be permitted to access the de-identified dataset contingent upon submission of a reasonable request and execution of appropriate data sharing agreements. To safeguard participant confidentiality and anonymity, all personally identifiable information is expunged prior to data dissemination. Trial Registration Number: ISRCTN13131584.

Acknowledgments

The authors extend their sincere gratitude to the patients and staff of the 4th Local Health Unit (TOMY) of Heraklion for their participation in this research endeavor. Additionally, we genuinely appreciate the generous donation of quercetin supplements by Green Import, exclusive distributor of Lamberts Healthcare Ltd. in Greece, while affirming that the company had no involvement in the conception, implementation, or evaluation of this study. The presented data and their interpretations and insights described are independent of any external influence or conflicting interest and solely attributable to the authors. We would also like to thank Malakates, Neonaki, and Tsikandylakis for their invaluable contribution to the conclusion of this study. Finally, we gratefully acknowledge Baoussis for his indispensable assistance. Aikaterini E. Mantadaki and Emmanouil K. Symvoulakis contributed equally to this work.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Gramatges, M.M.; Bertuch, A.A. Short Telomeres: From Dyskeratosis Congenita to Sporadic Aplastic Anemia and Malignancy. Transl. Res. 2013, 162, 353–363. [Google Scholar] [CrossRef]
  2. Dhillon, V.; Bull, C.; Fenech, M. Chapter 10—Telomeres, Aging, and Nutrition. In Molecular Basis of Nutrition and Aging; Malavolta, M., Mocchegiani, E., Eds.; Academic Press: San Diego, CA, USA, 2016; pp. 129–140. ISBN 978-0-12-801816-3. [Google Scholar]
  3. Maleki, M.; Khelghati, N.; Alemi, F.; Bazdar, M.; Asemi, Z.; Majidinia, M.; Sadeghpoor, A.; Mahmoodpoor, A.; Jadidi-Niaragh, F.; Targhazeh, N.; et al. Stabilization of Telomere by the Antioxidant Property of Polyphenols: Anti-Aging Potential. Life Sci. 2020, 259, 118341. [Google Scholar] [CrossRef]
  4. Ruiz, A.; Flores-Gonzalez, J.; Buendia-Roldan, I.; Chavez-Galan, L. Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases. Int. J. Mol. Sci. 2022, 23, 425. [Google Scholar] [CrossRef] [PubMed]
  5. Verdun, R.E.; Karlseder, J. Replication and Protection of Telomeres. Nature 2007, 447, 924–931. [Google Scholar] [CrossRef]
  6. Shammas, M.A. Telomeres, Lifestyle, Cancer, and Aging. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 28–34. [Google Scholar] [CrossRef]
  7. Oeseburg, H.; de Boer, R.A.; van Gilst, W.H.; van der Harst, P. Telomere Biology in Healthy Aging and Disease. Pflug. Arch. 2010, 459, 259–268. [Google Scholar] [CrossRef] [PubMed]
  8. Eppard, M.; Passos, J.F.; Victorelli, S. Telomeres, Cellular Senescence, and Aging: Past and Future. Biogerontology 2024, 25, 329–339. [Google Scholar] [CrossRef]
  9. Coppé, J.-P.; Desprez, P.-Y.; Krtolica, A.; Campisi, J. The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression. Annu. Rev. Pathol. 2010, 5, 99–118. [Google Scholar] [CrossRef]
  10. Daniali, L.; Benetos, A.; Susser, E.; Kark, J.D.; Labat, C.; Kimura, M.; Desai, K.; Granick, M.; Aviv, A. Telomeres Shorten at Equivalent Rates in Somatic Tissues of Adults. Nat. Commun. 2013, 4, 1597. [Google Scholar] [CrossRef] [PubMed]
  11. Fragkiadaki, P.; Renieri, E.; Kalliantasi, K.; Kouvidi, E.; Apalaki, E.; Vakonaki, E.; Mamoulakis, C.; Spandidos, D.A.; Tsatsakis, A. Τelomerase Inhibitors and Activators in Aging and Cancer: A Systematic Review. Mol. Med. Rep. 2022, 25, 158. [Google Scholar] [CrossRef] [PubMed]
  12. Kakridonis, F.; Pneumatikos, S.G.; Vakonaki, E.; Berdiaki, A.; Tzatzarakis, M.N.; Fragkiadaki, P.; Spandidos, D.A.; Baliou, S.; Ioannou, P.; Hatzidaki, E.; et al. Telomere Length as a Predictive Biomarker in Osteoporosis (Review). Biomed. Rep. 2023, 19, 87. [Google Scholar] [CrossRef]
  13. Fragkiadaki, P.; Nikitovic, D.; Kalliantasi, K.; Sarandi, E.; Thanasoula, M.; Stivaktakis, P.; Nepka, C.; Spandidos, D.; Theodoros, T.; Tsatsakis, A. Telomere Length and Telomerase Activity in Osteoporosis and Osteoarthritis (Review). Exp. Ther. Med. 2019, 19, 1626–1632. [Google Scholar] [CrossRef] [PubMed]
  14. Razgonova, M.P.; Zakharenko, A.M.; Golokhvast, K.S.; Thanasoula, M.; Sarandi, E.; Nikolouzakis, K.; Fragkiadaki, P.; Tsoukalas, D.; Spandidos, D.A.; Tsatsakis, A. Telomerase and Telomeres in Aging Theory and Chronographic Aging Theory (Review). Mol. Med. Rep. 2020, 22, 1679–1694. [Google Scholar] [CrossRef] [PubMed]
  15. Vakonaki, E.; Tsiminikaki, K.; Plaitis, S.; Fragkiadaki, P.; Tsoukalas, D.; Katsikantami, I.; Vaki, G.; Tzatzarakis, M.N.; Spandidos, D.A.; Tsatsakis, A.M. Common Mental Disorders and Association with Telomere Length. Biomed. Rep. 2018, 8, 111–116. [Google Scholar] [CrossRef] [PubMed]
  16. Fragkiadaki, P.; Tsoukalas, D.; Fragkiadoulaki, I.; Psycharakis, C.; Nikitovic, D.; Spandidos, D.A.; Tsatsakis, A.M. Telomerase Activity in Pregnancy Complications (Review). Mol. Med. Rep. 2016, 14, 16–21. [Google Scholar] [CrossRef]
  17. Apetroaei, M.-M.; Fragkiadaki, P.; Velescu, B.Ș.; Baliou, S.; Renieri, E.; Dinu-Pirvu, C.E.; Drăgănescu, D.; Vlăsceanu, A.M.; Nedea, M.I.; Udeanu, D.I.; et al. Pharmacotherapeutic Considerations on Telomere Biology: The Positive Effect of Pharmacologically Active Substances on Telomere Length. Int. J. Mol. Sci. 2024, 25, 7694. [Google Scholar] [CrossRef]
  18. Bonfigli, A.R.; Spazzafumo, L.; Prattichizzo, F.; Bonafè, M.; Mensà, E.; Micolucci, L.; Giuliani, A.; Fabbietti, P.; Testa, R.; Boemi, M.; et al. Leukocyte Telomere Length and Mortality Risk in Patients with Type 2 Diabetes. Oncotarget 2016, 7, 50835–50844. [Google Scholar] [CrossRef]
  19. Palmer, A.K.; Tchkonia, T.; LeBrasseur, N.K.; Chini, E.N.; Xu, M.; Kirkland, J.L. Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity. Diabetes 2015, 64, 2289–2298. [Google Scholar] [CrossRef]
  20. Mantadaki, A.E.; Linardakis, M.; Tsakiri, M.; Baliou, S.; Fragkiadaki, P.; Vakonaki, E.; Tzatzarakis, M.N.; Tsatsakis, A.; Symvoulakis, E.K. Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. J. Clin. Med. 2024, 13, 3504. [Google Scholar] [CrossRef]
  21. Palmer, A.K.; Gustafson, B.; Kirkland, J.L.; Smith, U. Cellular Senescence: At the Nexus between Ageing and Diabetes. Diabetologia 2019, 62, 1835–1841. [Google Scholar] [CrossRef]
  22. Narasimhan, A.; Flores, R.R.; Robbins, P.D.; Niedernhofer, L.J. Role of Cellular Senescence in Type II Diabetes. Endocrinology 2021, 162, bqab136. [Google Scholar] [CrossRef] [PubMed]
  23. Prattichizzo, F.; de Candia, P.; Ceriello, A. Diabetes and Kidney Disease: Emphasis on Treatment with SGLT-2 Inhibitors and GLP-1 Receptor Agonists. Metabolism 2021, 120, 154799. [Google Scholar] [CrossRef] [PubMed]
  24. Murakami, T.; Inagaki, N.; Kondoh, H. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells. Front. Endocrinol. 2022, 13, 869414. [Google Scholar] [CrossRef]
  25. Iwasaki, K.; Abarca, C.; Aguayo-Mazzucato, C. Regulation of Cellular Senescence in Type 2 Diabetes Mellitus: From Mechanisms to Clinical Applications. Diabetes Metab. J. 2023, 47, 441–453. [Google Scholar] [CrossRef] [PubMed]
  26. Martel, J.; Ojcius, D.M.; Wu, C.-Y.; Peng, H.-H.; Voisin, L.; Perfettini, J.-L.; Ko, Y.-F.; Young, J.D. Emerging Use of Senolytics and Senomorphics against Aging and Chronic Diseases. Med. Res. Rev. 2020, 40, 2114–2131. [Google Scholar] [CrossRef]
  27. Boccardi, V.; Paolisso, G. Telomerase Activation: A Potential Key Modulator for Human Healthspan and Longevity. Ageing Res. Rev. 2014, 15, 1–5. [Google Scholar] [CrossRef]
  28. Jafri, M.A.; Ansari, S.A.; Alqahtani, M.H.; Shay, J.W. Roles of Telomeres and Telomerase in Cancer, and Advances in Telomerase-Targeted Therapies. Genome Med. 2016, 8, 69. [Google Scholar] [CrossRef]
  29. Yuan, X.; Larsson, C.; Xu, D. Mechanisms Underlying the Activation of TERT Transcription and Telomerase Activity in Human Cancer: Old Actors and New Players. Oncogene 2019, 38, 6172–6183. [Google Scholar] [CrossRef]
  30. Zhang, L.; Pitcher, L.E.; Yousefzadeh, M.J.; Niedernhofer, L.J.; Robbins, P.D.; Zhu, Y. Cellular Senescence: A Key Therapeutic Target in Aging and Diseases. J. Clin. Investig. 2022, 132, e158450. [Google Scholar] [CrossRef]
  31. D’Andrea, G. Quercetin: A Flavonol with Multifaceted Therapeutic Applications? Fitoterapia 2015, 106, 256–271. [Google Scholar] [CrossRef]
  32. Mbara, K.C.; Devnarain, N.; Owira, P.M.O. Potential Role of Polyphenolic Flavonoids as Senotherapeutic Agents in Degenerative Diseases and Geroprotection. Pharm. Med. 2022, 36, 331–352. [Google Scholar] [CrossRef]
  33. Shao, Z.; Wang, B.; Shi, Y.; Xie, C.; Huang, C.; Chen, B.; Zhang, H.; Zeng, G.; Liang, H.; Wu, Y.; et al. Senolytic Agent Quercetin Ameliorates Intervertebral Disc Degeneration via the Nrf2/NF-κB Axis. Osteoarthr. Cartil. 2021, 29, 413–422. [Google Scholar] [CrossRef]
  34. Kim, S.R.; Jiang, K.; Ogrodnik, M.; Chen, X.; Zhu, X.-Y.; Lohmeier, H.; Ahmed, L.; Tang, H.; Tchkonia, T.; Hickson, L.J.; et al. Increased Renal Cellular Senescence in Murine High-Fat Diet: Effect of the Senolytic Drug Quercetin. Transl. Res. 2019, 213, 112–123. [Google Scholar] [CrossRef] [PubMed]
  35. Aghababaei, F.; Hadidi, M. Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals 2023, 16, 1020. [Google Scholar] [CrossRef] [PubMed]
  36. Chiang, M.-C.; Tsai, T.-Y.; Wang, C.-J. The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms. Int. J. Mol. Sci. 2023, 24, 6328. [Google Scholar] [CrossRef]
  37. Ioannou, P.; Baliou, S. The Molecular Mechanisms and Therapeutic Potential of Cranberry, D-Mannose, and Flavonoids against Infectious Diseases: The Example of Urinary Tract Infections. Antibiotics 2024, 13, 593. [Google Scholar] [CrossRef]
  38. Mantadaki, A.E.; Linardakis, M.; Vafeiadi, M.; Anastasiou, F.; Tsatsakis, A.; Symvoulakis, E.K. The Impact of Three-Month Quercetin Intake on Quality of Life and Anxiety in Patients with Type II Diabetes Mellitus: An Early Data Analysis from a Randomized Controlled Trial. Cureus 2024, 16, e58219. [Google Scholar] [CrossRef] [PubMed]
  39. Shatylo, V.; Antoniuk-Shcheglova, I.; Naskalova, S.; Bondarenko, O.; Havalko, A.; Krasnienkov, D.; Zabuga, O.; Kukharskyy, V.; Guryanov, V.; Vaiserman, A. Cardio-Metabolic Benefits of Quercetin in Elderly Patients with Metabolic Syndrome. PharmaNutrition 2021, 15, 100250. [Google Scholar] [CrossRef]
  40. O’Callaghan, N.J.; Fenech, M. A Quantitative PCR Method for Measuring Absolute Telomere Length. Biol. Proced. Online 2011, 13, 3. [Google Scholar] [CrossRef]
  41. Lai, T.-P.; Wright, W.E.; Shay, J.W. Comparison of Telomere Length Measurement Methods. Philos. Trans. R. Soc. B Biol. Sci. 2018, 373, 20160451. [Google Scholar] [CrossRef]
  42. O’Callaghan, N.J.; Dhillon, V.S.; Thomas, P.; Fenech, M. A Quantitative Real-Time PCR Method for Absolute Telomere Length. BioTechniques 2008, 44, 807–809. [Google Scholar] [CrossRef]
  43. Kahl, V.F.S.; Allen, J.A.M.; Nelson, C.B.; Sobinoff, A.P.; Lee, M.; Kilo, T.; Vasireddy, R.S.; Pickett, H.A. Telomere Length Measurement by Molecular Combing. Front. Cell Dev. Biol. 2020, 8, 493. [Google Scholar] [CrossRef] [PubMed]
  44. Lindrose, A.R.; McLester-Davis, L.W.Y.; Tristano, R.I.; Kataria, L.; Gadalla, S.M.; Eisenberg, D.T.A.; Verhulst, S.; Drury, S. Method Comparison Studies of Telomere Length Measurement Using qPCR Approaches: A Critical Appraisal of the Literature. PLoS ONE 2021, 16, e0245582. [Google Scholar] [CrossRef] [PubMed]
  45. ISRCTN—ISRCTN13131584: Study on the Benefit of Quercetin Intake in Diabetic Patients Treated with Antidiabetic Tablets. Available online: https://www.isrctn.com/ISRCTN13131584 (accessed on 14 July 2024).
  46. Behrens, Y.L.; Thomay, K.; Hagedorn, M.; Ebersold, J.; Henrich, L.; Nustede, R.; Schlegelberger, B.; Göhring, G. Comparison of Different Methods for Telomere Length Measurement in Whole Blood and Blood Cell Subsets: Recommendations for Telomere Length Measurement in Hematological Diseases. Genes Chromosomes Cancer 2017, 56, 700–708. [Google Scholar] [CrossRef] [PubMed]
  47. Butler, M.G.; Tilburt, J.; DeVries, A.; Muralidhar, B.; Aue, G.; Hedges, L.; Atkinson, J.; Schwartz, H. Comparison of Chromosome Telomere Integrity in Multiple Tissues from Subjects at Different Ages. Cancer Genet. Cytogenet. 1998, 105, 138–144. [Google Scholar] [CrossRef]
  48. Arai, Y.; Martin-Ruiz, C.M.; Takayama, M.; Abe, Y.; Takebayashi, T.; Koyasu, S.; Suematsu, M.; Hirose, N.; von Zglinicki, T. Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-Supercentenarians. EBioMedicine 2015, 2, 1549–1558. [Google Scholar] [CrossRef]
  49. Vaiserman, A.; Krasnienkov, D. Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives. Front. Genet. 2021, 11, 630186. [Google Scholar] [CrossRef]
  50. Shin, D.-Y.; Lim, K.M.; Park, H.S.; Kwon, S.; Yoon, S.-S.; Lee, D.-S. The Importance of Critically Short Telomere in Myelodysplastic Syndrome. Biomark. Res. 2022, 10, 79. [Google Scholar] [CrossRef]
  51. Whittemore, K.; Vera, E.; Martínez-Nevado, E.; Sanpera, C.; Blasco, M.A. Telomere Shortening Rate Predicts Species Life Span. Proc. Natl. Acad. Sci. USA 2019, 116, 15122–15127. [Google Scholar] [CrossRef]
  52. Yan, X.; Yang, P.; Li, Y.; Liu, T.; Zha, Y.; Wang, T.; Zhang, J.; Feng, Z.; Li, M. New Insights from Bidirectional Mendelian Randomization: Causal Relationships between Telomere Length and Mitochondrial DNA Copy Number in Aging Biomarkers. Aging 2024, 16, 7387. [Google Scholar] [CrossRef]
  53. Cheng, F.; Carroll, L.; Joglekar, M.V.; Januszewski, A.S.; Wong, K.K.; Hardikar, A.A.; Jenkins, A.J.; Ma, R.C.W. Diabetes, Metabolic Disease, and Telomere Length. Lancet Diabetes Endocrinol. 2021, 9, 117–126. [Google Scholar] [CrossRef] [PubMed]
  54. Cheng, F.; Luk, A.O.; Shi, M.; Huang, C.; Jiang, G.; Yang, A.; Wu, H.; Lim, C.K.P.; Tam, C.H.T.; Fan, B.; et al. Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care 2022, 45, 701–709. [Google Scholar] [CrossRef] [PubMed]
  55. Salpea, K.D.; Humphries, S.E. Telomere Length in Atherosclerosis and Diabetes. Atherosclerosis 2010, 209, 35–38. [Google Scholar] [CrossRef] [PubMed]
  56. Hickson, L.J.; Langhi Prata, L.G.P.; Bobart, S.A.; Evans, T.K.; Giorgadze, N.; Hashmi, S.K.; Herrmann, S.M.; Jensen, M.D.; Jia, Q.; Jordan, K.L.; et al. Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib plus Quercetin in Individuals with Diabetic Kidney Disease. EBioMedicine 2019, 47, 446–456. [Google Scholar] [CrossRef] [PubMed]
  57. Zhu, Y.; Tchkonia, T.; Pirtskhalava, T.; Gower, A.C.; Ding, H.; Giorgadze, N.; Palmer, A.K.; Ikeno, Y.; Hubbard, G.B.; Lenburg, M.; et al. The Achilles’ Heel of Senescent Cells: From Transcriptome to Senolytic Drugs. Aging Cell 2015, 14, 644–658. [Google Scholar] [CrossRef]
  58. Crous-Bou, M.; Molinuevo, J.-L.; Sala-Vila, A. Plant-Rich Dietary Patterns, Plant Foods and Nutrients, and Telomere Length. Adv. Nutr. 2019, 10, S296–S303. [Google Scholar] [CrossRef]
  59. Rahman, S.T.; Waterhouse, M.; Pham, H.; Romero, B.D.; Baxter, C.; McLeod, D.S.A.; English, D.R.; Ebeling, P.R.; Hartel, G.; Armstrong, B.K.; et al. Effects of Vitamin D Supplementation on Telomere Length: An Analysis of Data from the Randomised Controlled D-Health Trial. J. Nutr. Health Aging 2023, 27, 609–616. Available online: https://link.springer.com/article/10.1007/s12603-023-1948-3 (accessed on 18 July 2024). [CrossRef]
  60. Kiecolt-Glaser, J.K.; Epel, E.S.; Belury, M.A.; Andridge, R.; Lin, J.; Glaser, R.; Malarkey, W.B.; Hwang, B.S.; Blackburn, E. Omega-3 Fatty Acids, Oxidative Stress, and Leukocyte Telomere Length: A Randomized Controlled Trial. Brain Behav. Immun. 2013, 28, 16–24. [Google Scholar] [CrossRef]
  61. O’Callaghan, N.; Parletta, N.; Milte, C.M.; Benassi-Evans, B.; Fenech, M.; Howe, P.R.C. Telomere Shortening in Elderly Individuals with Mild Cognitive Impairment May Be Attenuated with ω-3 Fatty Acid Supplementation: A Randomized Controlled Pilot Study. Nutrition 2014, 30, 489–491. [Google Scholar] [CrossRef]
  62. Freitas-Simoes, T.-M.; Cofán, M.; Blasco, M.A.; Soberón, N.; Foronda, M.; Serra-Mir, M.; Roth, I.; Valls-Pedret, C.; Doménech, M.; Ponferrada-Ariza, E.; et al. Walnut Consumption for Two Years and Leukocyte Telomere Attrition in Mediterranean Elders: Results of a Randomized Controlled Trial. Nutrients 2018, 10, 1907. [Google Scholar] [CrossRef]
  63. Pusceddu, I.; Herrmann, M.; Kirsch, S.H.; Werner, C.; Hübner, U.; Bodis, M.; Laufs, U.; Widmann, T.; Wagenpfeil, S.; Geisel, J.; et al. One-Carbon Metabolites and Telomere Length in a Prospective and Randomized Study of B- and/or D-Vitamin Supplementation. Eur. J. Nutr. 2017, 56, 1887–1898. [Google Scholar] [CrossRef]
  64. Exploring the Effects of Dasatinib, Quercetin, and Fisetin on DNA Methylation Clocks: A Longitudinal Study on Senolytic Interventions—PMC. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10929829/ (accessed on 20 July 2024).
  65. Hachmo, Y.; Hadanny, A.; Hamed, R.A.; Daniel-Kotovsky, M.; Catalogna, M.; Fishlev, G.; Lang, E.; Polak, N.; Doenyas, K.; Friedman, M.; et al. Hyperbaric Oxygen Therapy Increases Telomere Length and Decreases Immunosenescence in Isolated Blood Cells: A Prospective Trial. Aging 2020, 12, 22445–22456. [Google Scholar] [CrossRef] [PubMed]
  66. Carroll, J.E.; Esquivel, S.; Goldberg, A.; Seeman, T.E.; Effros, R.B.; Dock, J.; Olmstead, R.; Breen, E.C.; Irwin, M.R. Insomnia and Telomere Length in Older Adults. Sleep 2016, 39, 559–564. [Google Scholar] [CrossRef] [PubMed]
  67. Tempaku, P.; Hirotsu, C.; Mazzotti, D.; Xavier, G.; Maurya, P.; Brietzke, E.; Belangero, S.; Poyares, D.; Bittencourt, L.; Tufik, S. Long Sleep Duration, Insomnia, and Insomnia with Short Objective Sleep Duration Are Independently Associated With Short Telomere Length. J. Clin. Sleep Med. 2018, 14, 2037–2045. [Google Scholar] [CrossRef]
  68. Jin, J.-H.; Kwon, H.S.; Choi, S.H.; Koh, S.-H.; Lee, E.-H.; Jeong, J.H.; Jang, J.-W.; Park, K.W.; Kim, E.-J.; Kim, H.J.; et al. Association between Sleep Parameters and Longitudinal Shortening of Telomere Length. Aging 2022, 14, 2930–2944. [Google Scholar] [CrossRef] [PubMed]
  69. Choi, E.S.; Chang, Y.K.; Lee, D.H.; Ko, J.-H.; Lim, I.; Bang, H.; Kim, J.-H. Gender-Specific Associations between Quality of Life and Leukocyte Telomere Length. Maturitas 2018, 107, 68–70. [Google Scholar] [CrossRef] [PubMed]
  70. Huzen, J.; van der Harst, P.; de Boer, R.A.; Lesman-Leegte, I.; Voors, A.A.; van Gilst, W.H.; Samani, N.J.; Jaarsma, T.; van Veldhuisen, D.J. Telomere Length and Psychological Well-Being in Patients with Chronic Heart Failure. Age Ageing 2010, 39, 223–227. [Google Scholar] [CrossRef]
  71. Tsur, N.; Levin, Y.; Abumock, H.; Solomon, Z. One ‘Knows’: Self-Rated Health and Telomere Length among Ex-Prisoners of War. Psychol. Health 2018, 33, 1503–1518. [Google Scholar] [CrossRef]
  72. Tellechea, M.L.; Pirola, C.J. The Impact of Hypertension on Leukocyte Telomere Length: A Systematic Review and Meta-Analysis of Human Studies. J. Hum. Hypertens. 2017, 31, 99–105. [Google Scholar] [CrossRef]
  73. Lung, F.-W.; Ku, C.-S.; Kao, W.-T. Telomere Length May Be Associated with Hypertension. J. Hum. Hypertens. 2008, 22, 230–232. [Google Scholar] [CrossRef]
  74. Monickaraj, F.; Aravind, S.; Gokulakrishnan, K.; Sathishkumar, C.; Prabu, P.; Prabu, D.; Mohan, V.; Balasubramanyam, M. Accelerated Aging as Evidenced by Increased Telomere Shortening and Mitochondrial DNA Depletion in Patients with Type 2 Diabetes. Mol. Cell. Biochem. 2012, 365, 343–350. [Google Scholar] [CrossRef] [PubMed]
  75. Ojeda-Rodriguez, A.; Morell-Azanza, L.; Alonso-Pedrero, L.; del Moral, A.M. Chapter 12—Aging, Telomere Integrity, and Antioxidant Food. In Obesity; del Moral, A.M., Aguilera García, C.M., Eds.; Academic Press: Cambridge, MA, USA, 2018; pp. 241–261. ISBN 978-0-12-812504-5. [Google Scholar] [CrossRef]
  76. Prasad, K.N.; Wu, M.; Bondy, S.C. Telomere Shortening during Aging: Attenuation by Antioxidants and Anti-Inflammatory Agents. Mech. Ageing Dev. 2017, 164, 61–66. [Google Scholar] [CrossRef] [PubMed]
  77. D’Angelo, S. Diet and Aging: The Role of Polyphenol-Rich Diets in Slow Down the Shortening of Telomeres: A Review. Antioxidants 2023, 12, 2086. [Google Scholar] [CrossRef] [PubMed]
  78. Heger, V.; Tyni, J.; Hunyadi, A.; Horáková, L.; Lahtela-Kakkonen, M.; Rahnasto-Rilla, M. Quercetin Based Derivatives as Sirtuin Inhibitors. Biomed. Pharmacother. 2019, 111, 1326–1333. [Google Scholar] [CrossRef]
  79. Ungurianu, A.; Zanfirescu, A.; Margină, D. Exploring the Therapeutic Potential of Quercetin: A Focus on Its Sirtuin-Mediated Benefits. Phytother. Res. 2024, 38, 2361–2387. [Google Scholar] [CrossRef] [PubMed]
  80. Cui, Z.; Zhao, X.; Amevor, F.K.; Du, X.; Wang, Y.; Li, D.; Shu, G.; Tian, Y.; Zhao, X. Therapeutic Application of Quercetin in Aging-Related Diseases: SIRT1 as a Potential Mechanism. Front. Immunol. 2022, 13, 943321. [Google Scholar] [CrossRef] [PubMed]
  81. Rahnasto-Rilla, M.; Tyni, J.; Huovinen, M.; Jarho, E.; Kulikowicz, T.; Ravichandran, S.; Bohr, V.A.; Ferrucci, L.; Lahtela-Kakkonen, M.; Moaddel, R. Natural Polyphenols as Sirtuin 6 Modulators. Sci. Rep. 2018, 8, 4163. [Google Scholar] [CrossRef] [PubMed]
  82. Su, Q.; Peng, M.; Zhang, Y.; Xu, W.; Darko, K.O.; Tao, T.; Huang, Y.; Tao, X.; Yang, X. Quercetin Induces Bladder Cancer Cells Apoptosis by Activation of AMPK Signaling Pathway. Am. J. Cancer Res. 2016, 6, 498–508. [Google Scholar]
  83. Guo, H.; Ding, H.; Tang, X.; Liang, M.; Li, S.; Zhang, J.; Cao, J. Quercetin Induces Pro-Apoptotic Autophagy via SIRT1/AMPK Signaling Pathway in Human Lung Cancer Cell Lines A549 and H1299 In Vitro. Thorac. Cancer 2021, 12, 1415–1422. [Google Scholar] [CrossRef]
  84. Shen, Y.; Croft, K.D.; Hodgson, J.M.; Kyle, R.; Lee, I.-L.E.; Wang, Y.; Stocker, R.; Ward, N.C. Quercetin and Its Metabolites Improve Vessel Function by Inducing eNOS Activity via Phosphorylation of AMPK. Biochem. Pharmacol. 2012, 84, 1036–1044. [Google Scholar] [CrossRef]
  85. Jacczak, B.; Rubiś, B.; Totoń, E. Potential of Naturally Derived Compounds in Telomerase and Telomere Modulation in Skin Senescence and Aging. Int. J. Mol. Sci. 2021, 22, 6381. [Google Scholar] [CrossRef] [PubMed]
  86. Khan, F.; Niaz, K.; Maqbool, F.; Ismail Hassan, F.; Abdollahi, M.; Nagulapalli Venkata, K.C.; Nabavi, S.M.; Bishayee, A. Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update. Nutrients 2016, 8, 529. [Google Scholar] [CrossRef] [PubMed]
  87. Ganesan, K.; Xu, B. Telomerase Inhibitors from Natural Products and Their Anticancer Potential. Int. J. Mol. Sci. 2018, 19, 13. [Google Scholar] [CrossRef]
  88. Parekh, N.; Garg, A.; Choudhary, R.; Gupta, M.; Kaur, G.; Ramniwas, S.; Shahwan, M.; Tuli, H.S.; Sethi, G. The Role of Natural Flavonoids as Telomerase Inhibitors in Suppressing Cancer Growth. Pharmaceuticals 2023, 16, 605. [Google Scholar] [CrossRef] [PubMed]
  89. Cui, S.; Wu, X.; Wang, Z.; Guo, Y.; Xu, R. Quercetin Regulates Telomere-Binding Proteins Expression of POT1, TRF1, TRF2 TO Inhibit Proliferation and Induce Apoptosis in AML THP-1 Cells. Available online: https://library.ehaweb.org/eha/2017/22nd/182385/ruirong.xu.quercetin.regulates.telomere-binding.proteins.expression.of.pot1.html (accessed on 22 July 2024).
  90. Avci, C.B.; Yilmaz, S.; Dogan, Z.O.; Saydam, G.; Dodurga, Y.; Ekiz, H.A.; Kartal, M.; Sahin, F.; Baran, Y.; Gunduz, C. Quercetin-Induced Apoptosis Involves Increased hTERT Enzyme Activity of Leukemic Cells. Hematology 2011, 16, 303–307. [Google Scholar] [CrossRef]
  91. Bhatiya, M.; Pathak, S.; Jothimani, G.; Duttaroy, A.K.; Banerjee, A. A Comprehensive Study on the Anti-Cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation. Arch. Immunol. Ther. Exp. 2023, 71, 6. [Google Scholar] [CrossRef]
  92. Zhu, J.; Cheng, X.; Naumovski, N.; Hu, L.; Wang, K. Epigenetic Regulation by Quercetin: A Comprehensive Review Focused on Its Biological Mechanisms. Crit. Rev. Food Sci. Nutr. 2023, 1–20. [Google Scholar] [CrossRef]
  93. Canela, A.; Vera, E.; Klatt, P.; Blasco, M.A. High-Throughput Telomere Length Quantification by FISH and Its Application to Human Population Studies. Proc. Natl. Acad. Sci. USA 2007, 104, 5300–5305. [Google Scholar] [CrossRef]
  94. Tsatsakis, A.; Tsoukalas, D.; Fragkiadaki, P.; Vakonaki, E.; Tzatzarakis, M.; Sarandi, E.; Nikitovic, D.; Tsilimidos, G.; Alegakis, A.K. Developing BIOTEL: A Semi-Automated Spreadsheet for Estimating Telomere Length and Biological Age. Front. Genet. 2019, 10, 84. [Google Scholar] [CrossRef]
  95. Dweck, A.; Maitra, R. The Advancement of Telomere Quantification Methods. Mol. Biol. Rep. 2021, 48, 5621–5627. [Google Scholar] [CrossRef]
  96. Vera, E.; Blasco, M.A. Beyond Average: Potential for Measurement of Short Telomeres. Aging 2012, 4, 379–392. [Google Scholar] [CrossRef] [PubMed]
  97. Joksic, G.; Joksic, I.; Filipović, J.; Liehr, T. Telomere Length Measurement by FISH. In Fluorescence In Situ Hybridization (FISH): Application Guide; Liehr, T., Ed.; Springer: Berlin/Heidelberg, Germany, 2017; pp. 147–152. ISBN 978-3-662-52959-1. [Google Scholar]
  98. Heritier, S.R.; Gebski, V.J.; Keech, A.C. Inclusion of Patients in Clinical Trial Analysis: The Intention-to-Treat Principle. Med. J. Aust. 2003, 179, 438–440. [Google Scholar] [CrossRef] [PubMed]
  99. Matacchione, G.; Perugini, J.; Di Mercurio, E.; Sabbatinelli, J.; Prattichizzo, F.; Senzacqua, M.; Storci, G.; Dani, C.; Lezoche, G.; Guerrieri, M.; et al. Senescent Macrophages in the Human Adipose Tissue as a Source of Inflammaging. Geroscience 2022, 44, 1941–1960. [Google Scholar] [CrossRef] [PubMed]
  100. Faul, F.; Erdfelder, E.; Lang, A.-G.; Buchner, A. G*Power 3: A Flexible Statistical Power Analysis Program for the Social, Behavioral, and Biomedical Sciences. Behav. Res. Methods 2007, 39, 175–191. [Google Scholar] [CrossRef] [PubMed]
  101. Faul, F.; Erdfelder, E.; Buchner, A.; Lang, A.-G. Statistical Power Analyses Using G*Power 3.1: Tests for Correlation and Regression Analyses. Behav. Res. Methods 2009, 41, 1149–1160. [Google Scholar] [CrossRef]
  102. Kiecolt-Glaser, J.K.; Belury, M.A.; Andridge, R.; Malarkey, W.B.; Hwang, B.S.; Glaser, R. Omega-3 Supplementation Lowers Inflammation in Healthy Middle-Aged and Older Adults: A Randomized Controlled Trial. Brain Behav. Immun. 2012, 26, 988–995. [Google Scholar] [CrossRef]
  103. Harrigan, M.; Cartmel, B.; Loftfield, E.; Sanft, T.; Chagpar, A.B.; Zhou, Y.; Playdon, M.; Li, F.; Irwin, M.L. Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. J. Clin. Oncol. 2016, 34, 669–676. [Google Scholar] [CrossRef]
  104. Sanft, T.; Usiskin, I.; Harrigan, M.; Cartmel, B.; Lu, L.; Li, F.-Y.; Zhou, Y.; Chagpar, A.; Ferrucci, L.M.; Pusztai, L.; et al. Randomized Controlled Trial of Weight Loss versus Usual Care on Telomere Length in Women with Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. Breast Cancer Res. Treat. 2018, 172, 105–112. [Google Scholar] [CrossRef]
  105. Opstad, T.B.; Alexander, J.; Aaseth, J.O.; Larsson, A.; Seljeflot, I.; Alehagen, U. Selenium and Coenzyme Q10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial. Nutrients 2022, 14, 3346. [Google Scholar] [CrossRef]
  106. Ward, S.J.; Hill, A.M.; Buckley, J.D.; Banks, S.; Dhillon, V.S.; Holman, S.L.; Morrison, J.L.; Coates, A.M. Minimal Changes in Telomere Length after a 12-Week Dietary Intervention with Almonds in Mid-Age to Older, Overweight and Obese Australians: Results of a Randomised Clinical Trial. Br. J. Nutr. 2022, 127, 872–884. [Google Scholar] [CrossRef]
  107. Denham, J.; O’Brien, B.J.; Prestes, P.R.; Brown, N.J.; Charchar, F.J. Increased Expression of Telomere-Regulating Genes in Endurance Athletes with Long Leukocyte Telomeres. J. Appl. Physiol. 2016, 120, 148–158. [Google Scholar] [CrossRef] [PubMed]
  108. Manchia, M.; Paribello, P.; Arzedi, C.; Bocchetta, A.; Caria, P.; Cocco, C.; Congiu, D.; Cossu, E.; Dettori, T.; Frau, D.V.; et al. A Multidisciplinary Approach to Mental Illness: Do Inflammation, Telomere Length and Microbiota Form a Loop? A Protocol for a Cross-Sectional Study on the Complex Relationship between Inflammation, Telomere Length, Gut Microbiota and Psychiatric Disorders. BMJ Open 2020, 10, e032513. [Google Scholar] [CrossRef]
  109. Franzoni, L.T.; Garcia, E.L.; Motta, S.B.; Ahner, M.M.; Bertoletti, O.A.; Saffi, M.A.L.; da Silveira, A.D.; Pereira, A.A.; Pereira, A.H.; Danzmann, L.C.; et al. Aerobic Exercise and Telomere Length in Patients with Systolic Heart Failure: Protocol Study for a Randomized Controlled Trial. Trials 2022, 23, 283. [Google Scholar] [CrossRef] [PubMed]
  110. Tsoukalas, D.; Fragkiadaki, P.; Docea, A.O.; Alegakis, A.K.; Sarandi, E.; Vakonaki, E.; Salataj, E.; Kouvidi, E.; Nikitovic, D.; Kovatsi, L.; et al. Association of Nutraceutical Supplements with Longer Telomere Length. Int. J. Mol. Med. 2019, 44, 218–226. [Google Scholar] [CrossRef] [PubMed]
  111. Tsatsakis, A.; Renieri, E.; Tsoukalas, D.; Buga, A.M.; Sarandi, E.; Vakonaki, E.; Fragkiadaki, P.; Alegakis, A.; Nikitovic, D.; Calina, D.; et al. A Novel Nutraceutical Formulation Increases Telomere Length and Activates Telomerase Activity in Middle-aged Rats. Mol. Med. Rep. 2023, 28, 1–11. [Google Scholar] [CrossRef]
  112. Chung, S.S.; Dutta, P.; Chard, N.; Wu, Y.; Chen, Q.-H.; Chen, G.; Vadgama, J. A Novel Curcumin Analog Inhibits Canonical and Non-Canonical Functions of Telomerase through STAT3 and NF-κB Inactivation in Colorectal Cancer Cells. Oncotarget 2019, 10, 4516–4531. [Google Scholar] [CrossRef]
  113. Precision in qPCR—GR. Available online: https://www.thermofisher.com/tr/en/home/life-science/pcr/real-time-pcr/real-time-pcr-learning-center/gene-expression-analysis-real-time-pcr-information/precision-qpcr.html (accessed on 20 July 2024).
  114. Taylor, S.; Wakem, M.; Dijkman, G.; Alsarraj, M.; Nguyen, M. A Practical Approach to RT-qPCR—Publishing Data That Conform to the MIQE Guidelines. Methods 2010, 50, S1–S5. [Google Scholar] [CrossRef]
  115. Kitchen, R.R.; Kubista, M.; Tichopad, A. Statistical Aspects of Quantitative Real-Time PCR Experiment Design. Methods 2010, 50, 231–236. [Google Scholar] [CrossRef]
  116. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
  117. Schmittgen, T.D.; Livak, K.J. Analyzing Real-Time PCR Data by the Comparative CT Method. Nat. Protoc. 2008, 3, 1101–1108. [Google Scholar] [CrossRef]
  118. Linardakis, M.; Papadaki, A.; Smpokos, E.; Kafatos, A.; Lionis, C. Prevalence of Multiple Behavioral Risk Factors for Chronic Diseases in Medical Students and Associations with Their Academic Performance. J. Public Health 2020, 28, 383–392. [Google Scholar] [CrossRef]
  119. Linardakis, M.; Papadaki, A.; Smpokos, E.; Micheli, K.; Vozikaki, M.; Philalithis, A. Relationship of Behavioral Risk Factors for Chronic Diseases and Preventive Health Services Utilization among Adults, Aged 50+, from Eleven European Countries. J. Public Health 2015, 23, 257–265. [Google Scholar] [CrossRef]
  120. Symvoulakis, E.K.; Stachteas, P.; Smyrnakis, E.; Volkos, P.; Mantadaki, A.E.; Karelis, A.; Petraki, C.; Nioti, K.; Mastronikolis, S.; Antoniou, A.M.; et al. Multiple Behavioral Risk Factors As Assets for Chronic Disease Prevention: Observations From Urban Primary Care Settings in Crete, Greece. Cureus 2024, 16, e56711. [Google Scholar] [CrossRef]
  121. Nagelkerke, N.J.D. A Note on a General Definition of the Coefficient of Determination. Biometrika 1991, 78, 691–692. [Google Scholar] [CrossRef]
  122. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. Available online: https://ichgcp.net/home (accessed on 25 April 2024).
  123. European Medicines Agency Guideline for Good Clinical Practice E6 (R2). Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-4-step-2b_en.pdf (accessed on 22 March 2024).
  124. European Parliament and the Council of the European Union Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC. Available online: https://health.ec.europa.eu/document/download/f724d198-9ec8-4cad-9ce7-b6d2ac1ec44e_en (accessed on 22 March 2024).
  125. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 2013, 310, 2191–2194. [Google Scholar] [CrossRef] [PubMed]
  126. Moher, D.; Hopewell, S.; Schulz, K.F.; Montori, V.; Gøtzsche, P.C.; Devereaux, P.J.; Elbourne, D.; Egger, M.; Altman, D.G. CONSORT 2010 Explanation and Elaboration: Updated Guidelines for Reporting Parallel Group Randomised Trials. BMJ 2010, 340, c869. [Google Scholar] [CrossRef]
  127. World Health Organization. Handbook for Good Clinical Research Practice (GCP): Guidance for Implementation; World Health Organization: Geneva, Switzerland, 2005; Available online: https://iris.who.int/bitstream/handle/10665/43392/924159392X_eng.pdf (accessed on 14 July 2024).
  128. International Council For Harmonisation (ICH). Harmonised Guideline on Genomic Sampling and Management of Genomic Data E18. Available online: https://database.ich.org/sites/default/files/E18_Guideline.pdf (accessed on 14 July 2024).
  129. European Medicines Agency (EMA). ICH Guideline E18 on Genomic Sampling and Management of Genomic Data. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e18-genomic-sampling-and-management-genomic-data-step-3_en.pdf (accessed on 14 July 2024).
Pharmaceuticals 17 01136 g001
Figure 1. Flow diagram for the TL analysis subcohort, aligning with CONSORT standards.
Figure 1. Flow diagram for the TL analysis subcohort, aligning with CONSORT standards.
Pharmaceuticals 17 01136 g001
Pharmaceuticals 17 01136 g002
Figure 2. Frequency of telomere length (TL) changes (increase or decrease) in patients with type 2 diabetes mellitus (T2DM) consenting to blood sampling for whole-blood TL measurements, randomized to intervention (n = 40) and control (n = 42) groups over the 8-month study period.
Figure 2. Frequency of telomere length (TL) changes (increase or decrease) in patients with type 2 diabetes mellitus (T2DM) consenting to blood sampling for whole-blood TL measurements, randomized to intervention (n = 40) and control (n = 42) groups over the 8-month study period.
Pharmaceuticals 17 01136 g002
Table 1. Baseline descriptive characteristics of the 82 patients with type II diabetes (T2DM) consenting to blood sampling for telomere length (TL) measurements and randomized to intervention and control groups.
Table 1. Baseline descriptive characteristics of the 82 patients with type II diabetes (T2DM) consenting to blood sampling for telomere length (TL) measurements and randomized to intervention and control groups.
Groups
Intervention (n = 40)Control (n = 42)
n (%)
Sexmale22 (55.0)23 (54.8)
female18 (45.0)19 (45.2)
Age, yearsmean ± stand. dev.66.3 ± 7.467.8 ± 6.2
NationalityGreek36 (90.0)42 (100.0)
Lifestyle Risk Factorssmoking13 (32.5)15 (35.7)
alcohol consumption28 (70.0)28 (66.7)
high body weight35 (87.5)39 (92.9)
physical inactivity16 (40.0)21 (50.0)
not consuming fruits2 (5.0)2 (4.8)
3+ factors16 (40.0)23 (54.8)
Multimorbidity3+ chronic conditions32 (80.0)28 (66.7)
Polypharmacy4+ medications28 (70.0)29 (69.0)
Years diagnosed with T2DMmean ± stand. dev.11.0 ± 7.110.3 ± 6.6
Chi-square (χ2) and Student’s t-tests: * p < 0.05.
Table 2. Levels of and changes in health indicators of the 82 patients with T2DM consenting to blood sampling for whole-blood TL measurements and randomized to intervention (n = 40) and control (n = 42) groups from the starting point to the endpoint of the study.
Table 2. Levels of and changes in health indicators of the 82 patients with T2DM consenting to blood sampling for whole-blood TL measurements and randomized to intervention (n = 40) and control (n = 42) groups from the starting point to the endpoint of the study.
Groups
InterventionControl Cohen’s d Effect Size
Mean ± Stand. Dev.p-Value
Night-time sleep (hours)beginning6.2 ± 1.76.6 ± 1.5
8 months7.0 ± 1.36.1 ± 1.7
Δ-change+0.8−0.5<0.0010.93
p-value0.0020.011
Health self-assessment (scale 0 to 10, 10: excellent)beginning6.0 ± 2.15.9 ± 2.1
8 months7.5 ± 1.75.3 ± 2.0
Δ-change+1.5−0.6<0.0011.56
p-value<0.0010.005
Body mass index (kg/m2)beginning31.4 ± 5.130.6 ± 5.4
8 months31.0 ± 5.130.3 ± 5.2
Δ-change−0.4−0.30.7800.05
p-value0.0120.089
Systolic blood pressure (mmHg)beginning130.7 ± 14.2128.4 ± 13.8
8 months124.4 ± 13.8128.9 ± 16.5
Δ-change−6.3+0.50.0200.52
p-value0.0030.804
Diastolic blood pressure (mmHg)beginning76.0 ± 8.875.4 ± 10.7
8 months77.4 ± 9.177.3 ± 8.8
Δ-change+1.4+1.90.8220.05
p-value0.2760.196
Total cholesterol (mg/dL)beginning154.9 ± 35.9163.7 ± 37.6
8 months160.4 ± 36.4163.9 ± 44.4
Δ-change+5.5+0.20.4600.17
p-value0.1220.966
Glycosylated hemoglobin (HbA1c) (%)beginning7.03 ± 1.126.71 ± 0.79
8 months6.75 ± 0.896.74 ± 0.94
Δ-change−0.28+0.030.0080.60
p-value0.0050.655
Cholesterol ratiobeginning3.937 ± 1.9623.567 ± 0.927
8 months3.855 ± 1.4034.109 ± 2.147
Δ-change−0.072+0.7520.0700.41
p-value0.8020.035
Telomere length (kb)beginning5.11 ± 1.355.19 ± 1.76
8 months5.63 ± 2.084.88 ± 1.19
Δ-change+0.52−0.310.0480.44
p-value0.1200.235
Student’s t-tests in Δ-changes (in bold) and paired samples t-tests between the baseline and study endpoint for each group (in grey).
Table 3. Multiple logistic regression analysis of TL increase (versus decrease) over the 8-month study period among the 82 patients with T2DM consenting to blood sampling for whole-blood TL measurements and randomized to intervention (n = 40) and control (n = 42) groups.
Table 3. Multiple logistic regression analysis of TL increase (versus decrease) over the 8-month study period among the 82 patients with T2DM consenting to blood sampling for whole-blood TL measurements and randomized to intervention (n = 40) and control (n = 42) groups.
Telomere Length Changes over the 8-Month Study Period (Increase vs. Decrease)
ModelPrognostic Factors Odds Ratio, OR95% CIsp-Value
CrudeGroupscontrol1.00 (ref.)
intervention2.441.00, 5.930.050
1Baseline Telomeres (per unit change)0.520.35, 0.790.002
Groupscontrol1.00 (ref.)
intervention2.871.07, 7.700.036
2Sexmale1.00 (ref.)
female1.640.60, 4.520.336
Age (per year change)0.950.88, 1.020.167
Baseline Telomeres (per unit change)0.490.32, 0.760.002
Groupscontrol1.00 (ref.)
intervention2.901.05, 8.000.040
3Sexmale1.00 (ref.)
female1.990.66, 5.960.221
Age (per year change)0.940.86, 1.020.137
Baseline Telomeres (per unit change)0.480.30, 0.760.002
Lifestyle Risk Factors0–2 factors1.00 (ref.)
3+ 2.230.75, 6.630.148
Multimorbidity0–2 chronic conditions1.00 (ref.)
3+ 0.610.17, 2.200.453
Polypharmacy0–3 medications1.00 (ref.)
4+ 0.930.28, 3.100.909
Years Diagnosed with T2DM (per year change)1.060.97, 1.150.186
Groupscontrol1.00 (ref.)
intervention3.481.16, 10.410.026
R2 Nagelkerke estimations: Crude model R2 = 0.06; 1st model R2 = 0.25; 2nd model R2 = 0.30; 3rd model R2 = 0.33.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mantadaki, A.E.; Baliou, S.; Linardakis, M.; Vakonaki, E.; Tzatzarakis, M.N.; Tsatsakis, A.; Symvoulakis, E.K. Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study. Pharmaceuticals 2024, 17, 1136. https://doi.org/10.3390/ph17091136

AMA Style

Mantadaki AE, Baliou S, Linardakis M, Vakonaki E, Tzatzarakis MN, Tsatsakis A, Symvoulakis EK. Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study. Pharmaceuticals. 2024; 17(9):1136. https://doi.org/10.3390/ph17091136

Chicago/Turabian Style

Mantadaki, Aikaterini E., Stella Baliou, Manolis Linardakis, Elena Vakonaki, Manolis N. Tzatzarakis, Aristides Tsatsakis, and Emmanouil K. Symvoulakis. 2024. "Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study" Pharmaceuticals 17, no. 9: 1136. https://doi.org/10.3390/ph17091136

APA Style

Mantadaki, A. E., Baliou, S., Linardakis, M., Vakonaki, E., Tzatzarakis, M. N., Tsatsakis, A., & Symvoulakis, E. K. (2024). Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study. Pharmaceuticals, 17(9), 1136. https://doi.org/10.3390/ph17091136

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop